openPR Logo
Press release

Antibodies Market to Surpass US$ 105 Bn in Revenues in 2016

07-29-2016 10:20 AM CET | Health & Medicine

Press release from: Future Market Insights

Antibodies Market to Surpass US$ 105 Bn in Revenues in 2016

High rate of product approvals, combined with rising adoption of therapeutic antibodies in developing economies is positively influencing the growth of the global antibodies market, with total revenues expected to surpass US$ 105 Bn in 2016. Approval of monoclonal antibody products, including therapeutic antibodies, drug conjugates, and antibody fragments in key markets of the U.S., Europe, and Japan have bolstered the growth of the global antibodies market. Availability of inexpensive biosimilar antibody therapeutics is also bolstering the growth of the antibody market.

While the short- and long-term outlook on the global antibodies market remains positive, side effects associated with antibody treatment and failure of investigational drugs in late stages of development can pose challenges to widespread adoption. Administration of antibodies has been linked to serum sickness and acute anaphylaxis, posing challenges to widespread adoption.

By drug type, monoclonal antibodies will continue to dominate demand, accounting for nearly 95% share of the market in 2016. Of the US$ 105 Bn worth of antibodies therapeutics expected to be sold in 2016, monoclonal antibodies will account for US$ 99.81 Bn. Polyclonal antibodies and antibody-drug complexes will represent minority share of the global market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1330

Hospitals will remain the largest end-users in the global antibodies market, accounting for over 85% revenue share in 2016. Demand for antibodies from hospitals end-use segment will witness a year-over-year growth rate of over 12% and surpass US$ 90 Bn in revenues.

By disease indication, the key segments of the global antibodies market include CNS disorders, cardiovascular diseases, cancer, and autoimmune disorders. Cancer remains the most prominent indication segment, accounting for nearly 54% revenue share in 2016. Cardiovascular diseases is the smallest segment in the global antibodies market in terms of revenues, and will witness the lowest growth rates among all the indication segments.

North America will continue to remain the largest market in the global antibodies market, accounting for nearly 44% revenue share of the market in 2016. In the U.S. therapeutic antibody products are subject to submission of biologics licence application (BLA), whereas in Canada, Biologics and Genetic Therapies Directorate (BGTD) governs the approval of biological products. The U.S. accounts for the majority revenue share of the North America antibodies market, and will witness a higher growth rate than Canada.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1330

In addition to North America, Western Europe and APEJ will continue to remain the other top markets for antibodies. While the U.K., Germany, and France will remain the top 3 markets in Western Europe, demand for antibodies in APEJ will remain largely concentrated in China, India, and ASEAN.

F. Hoffmann-La Roche AG, AbbVie Inc., and Johnson & Johnson will maintain their position as the top 3 players in the global antibodies market. These 3 players collectively account for nearly 57% revenue share of the global antibodies market. Herceptin, Avastin (Roche), Humira (AbbVie), and Remicade (J&J) are the blockbuster drugs in the global antibodies market. Other key players in the market are Amgen Inc., Bristol-Myers Squibb Company, Biogen Inc., Merck & Co, and Novartis. Gaining product approvals from EU and FDA and strengthening collaborations with distribution partners remains a key strategy for leading players in the global antibodies market.

Browse the full "Antibodies Market: Global Industry Analysis and Opportunity Assessment, 2016 - 2016"market research report at http://www.futuremarketinsights.com/reports/antibodies-market

Long-term Outlook: The global antibodies market is expected to increase at a CAGR of 12.5% during the forecast period 2016-2026 and surpass US$ 341 Bn in revenues.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibodies Market to Surpass US$ 105 Bn in Revenues in 2016 here

News-ID: 352757 • Views:

More Releases from Future Market Insights

Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Modeling and VR Innovation
Workstation Software Market to Soar to USD 43.9 Billion by 2035, Fueled by 3D Mo …
Rising Demand for Workstation Software Across Industries The global workstation software market is set for robust growth, driven by increasing demand for advanced visualization, simulation, and design tools across industries such as manufacturing, architecture, media, and entertainment. Valued at USD 14.8 billion in 2025, the market is projected to reach USD 43.9 billion by 2035, registering a compound annual growth rate (CAGR) of 11.5%. This surge reflects the rising complexity of
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
Bean Flour Market Set for Robust Growth in the USA at 6.27% CAGR Through 2035
The global bean flour market is entering a period of remarkable expansion, driven by surging demand for plant-based nutrition and gluten-free alternatives. Analysts forecast the market to grow from USD 5,075.3 million in 2025 to USD 9,262.0 million by 2035, reflecting a CAGR of 6.2%. This trajectory highlights an unparalleled opportunity for manufacturers to address evolving consumer preferences while enhancing sustainability and profitability. As the world shifts towards cleaner diets and
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
Blueberry Ingredient Market Set to Soar with 6.27% Growth in the USA by 2035
The blueberry ingredient industry has firmly established itself as a cornerstone of the functional foods, nutraceuticals, and natural flavoring sectors. Analysts project the market valuation to reach approximately USD 2.8 billion by 2025, with a robust CAGR of 6.5% forecasted from 2025 to 2035. This growth is being fueled by the escalating demand for clean-label products, plant-based formulations, and functional solutions across the food, beverage, and cosmetic industries. Click Here for
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Transform Baking Innovation by 2035
Activated Cake Emulsifier Market Set for 6.27% Growth in the USA, Poised to Tran …
The activated cake emulsifier market is entering a transformative phase, driven by evolving consumer preferences toward premium, high-quality bakery products. Estimated to reach USD 1,343.2 million in 2025, the market is projected to achieve USD 2,360.5 million by 2035, representing a robust 5.8% CAGR over the next decade. This growth offers a strategic opportunity for manufacturers to meet rising consumer demands while future-proofing operations through innovation, regional customization, and sustainability. Click

All 5 Releases


More Releases for Antibodies

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The arthritis monoclonal antibodies
Global Multispecific Antibodies Market Size Antibodies Sales Forecast 2029
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights: • Global & Regional Market Analysis • Global Multispecific Antibodies Market Opportunity: > USD 40 Billion • Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion • Number Of Approved Multispecific Antibodies: 14 • Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight • Approved Antibodies Dosage & Pricing Insight • Number Of Multispecific Antibodies: In Clinical Trials: > 900 • Comprehensive Insight On All Antibodies In Clinical Trials By
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: • Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms • Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023) • Global Bispecific Antibodies Market Size 2023: > USD 8 Billion • Global Bispecific Antibodies Market Forecast Till 2029 • Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023) • Approved Bispecific Antibodies Regional Sales (2018 till 2023) • Clinical and Commercial Insight On Approved
Emergence of Tetravalent Antibodies
The emergence of tetravalent antibodies represents a significant advancement in the field of therapeutic antibodies, offering new possibilities for treating complex diseases such as cancer, infectious diseases, and autoimmune disorders. These innovative molecules, capable of binding to four antigens or epitopes simultaneously, provide enhanced specificity, efficacy, and versatility, addressing the limitations of traditional monoclonal and even bispecific antibodies. Download Bispecific, Trispecific and Tetraspecific Antibodies Report: https://www.kuickresearch.com/ccformF.php?t=1721642510 Tetravalent antibodies are designed to engage